Report Overview

The global Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market size is estimated to be valued at US$ 964.6 million in 2019 and is expected to exhibit a CAGR of 4.4% between 2019 and 2028.

The increase in the prevalence of MRSA infections and number of hospitals, growing awareness about a bacterial infection, and increase in immuno-compromised population are expected to enhance the market growth. However, the high cost of novel MRSA drugs and hospital readmissions reduction program is projected to curb the growth of the market.



Market Drivers

MRSA drugs have been gaining significant growth in recent years owing to the rising awareness about MRSA infections. For instance, October is celebrated as world MRSA awareness month and November 18, is celebrated as antibiotic awareness day in Europe to raise awareness of antibiotic resistance and promote the judicious use of antibiotics. Thus, the growing awareness about the cause and treatment related to bacterial infection among the population led to an increased usage of MRSA drug market, which thereby provides a favourable scenario for the market to grow during the forecast period

Growing incidence of infections associated with Methicillin-resistant staphylococcus aureus (MRSA) pathogens is creating health concerns among the population. Manufacturers are focusing on product development and launches for the treatment of Methicillin-resistant staphylococcus aureus (MRSA), which is expected to boost the Methicillin-resistant staphylococcus aureus (MRSA) drugs market growth. For instance, in February 2019, Paratek Pharmaceuticals, Inc. launched NUZYRA (omadacycline) in the U.S. market. The drug is available in a once-daily intravenous and oral antibiotic. It is specifically designed to overcome tetracycline resistance and exhibits activity across a spectrum of bacteria, including gram-positive, gram-negative, atypical, and other drug-resistant strains.